| scholarly article | Q13442814 |
| P50 | author | Barton Haynes | Q4865631 |
| Beatrice H. Hahn | Q55293537 | ||
| David C. Montefiori | Q63302725 | ||
| Georgia D. Tomaras | Q63663866 | ||
| Brandon Keele | Q68690678 | ||
| George M. Shaw | Q78514357 | ||
| Kent J. Weinhold | Q109935303 | ||
| Jennifer L Kirchherr | Q114406376 | ||
| P2093 | author name string | Feng Gao | |
| Xiaoying Shen | |||
| William A Blattner | |||
| Julie M Decker | |||
| Michael L Greenberg | |||
| Charles B Hicks | |||
| Robert J Parks | |||
| P2860 | cites work | A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies | Q27485578 |
| Aiming to induce broadly reactive neutralizing antibody responses with HIV-1 vaccine candidates | Q27489000 | ||
| Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein | Q28140278 | ||
| Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies | Q29619015 | ||
| Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection | Q29619510 | ||
| Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. | Q31016954 | ||
| An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10 | Q33272711 | ||
| Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis | Q33592278 | ||
| Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope | Q34348303 | ||
| Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. | Q34434854 | ||
| Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors | Q35857221 | ||
| Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection | Q35857268 | ||
| In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. | Q35947769 | ||
| Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection | Q36423897 | ||
| 4E10-resistant variants in a human immunodeficiency virus type 1 subtype C-infected individual with an anti-membrane-proximal external region-neutralizing antibody response | Q36483956 | ||
| Antibody polyspecificity and neutralization of HIV-1: a hypothesis | Q36487151 | ||
| The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design | Q36497712 | ||
| Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. | Q36974754 | ||
| Broad HIV-1 neutralization mediated by CD4-binding site antibodies | Q36977635 | ||
| Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection | Q37033294 | ||
| Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals | Q37033400 | ||
| Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles | Q37251390 | ||
| Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. | Q37683080 | ||
| Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma | Q40311562 | ||
| Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies | Q40344651 | ||
| Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. | Q40429324 | ||
| Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. | Q41171978 | ||
| Generation of Human Monoclonal Antibodies against HIV-1 Proteins; Electrofusion and Epstein-Barr Virus Transformation for Peripheral Blood Lymphocyte Immortalization | Q41478638 | ||
| Rapid clearance of virus after acute HIV-1 infection: correlates of risk of AIDS. | Q45644537 | ||
| Restricted antigenic variability of the epitope recognized by the neutralizing gp41 antibody 2F5 | Q58038933 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | monoclonal antibody | Q422248 |
| antibody | Q79460 | ||
| P304 | page(s) | 3617-3625 | |
| P577 | publication date | 2009-02-04 | |
| P1433 | published in | Journal of Virology | Q1251128 |
| P1476 | title | In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth | |
| P478 | volume | 83 |
| Q34396912 | A fusion intermediate gp41 immunogen elicits neutralizing antibodies to HIV-1 |
| Q27676864 | A gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen Recognition |
| Q37363517 | Amino Acid Changes in the HIV-1 gp41 Membrane Proximal Region Control Virus Neutralization Sensitivity |
| Q37680009 | An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. |
| Q26774672 | Anergic B Cells: Precarious On-Call Warriors at the Nexus of Autoimmunity and False-Flagged Pathogens |
| Q33794973 | Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines |
| Q37333772 | Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors |
| Q30408097 | Antibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination Strategies |
| Q55436995 | Antibody-Mediated Therapy against HIV/AIDS: Where Are We Standing Now? |
| Q38072056 | Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design. |
| Q36363231 | Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family |
| Q84223236 | Antigen-specific enhancement of natural human IgG antibodies to phosphatidylcholine, phosphatidylglycerol, phosphatidylinositol-4-phosphate, cholesterol, and lipid A by a liposomal vaccine containing lipid A |
| Q35060573 | Antigenic analysis of monoclonal antibodies against different epitopes of σB protein of avian reovirus |
| Q36267348 | Antigenic characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor incorporated into nanodiscs |
| Q34022578 | Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination |
| Q33591736 | Autoreactivity in an HIV-1 broadly reactive neutralizing antibody variable region heavy chain induces immunologic tolerance |
| Q35689608 | Binding of Anti-Membrane-Proximal gp41 Monoclonal Antibodies to CD4-Liganded and -Unliganded Human Immunodeficiency Virus Type 1 and Simian Immunodeficiency Virus Virions |
| Q37410792 | Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region |
| Q44176443 | Changing sensitivity to broadly neutralizing antibodies b12, 2G12, 2F5, and 4E10 of primary subtype B human immunodeficiency virus type 1 variants in the natural course of infection |
| Q33798076 | Characteristics of the earliest cross-neutralizing antibody response to HIV-1. |
| Q44665312 | Characterization of a trimeric MPER containing HIV-1 gp41 antigen |
| Q39469638 | Comprehensive mapping of West Nile virus (WNV)- and Japanese encephalitis virus serocomplex-specific linear B-cell epitopes from WNV non-structural protein 1 |
| Q34006748 | Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies |
| Q38959483 | Differential reactivity of germ line allelic variants of a broadly neutralizing HIV-1 antibody to a gp41 fusion intermediate conformation |
| Q42850455 | Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity |
| Q34594036 | Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. |
| Q36956100 | Engineering Recombinant Reoviruses To Display gp41 Membrane-Proximal External-Region Epitopes from HIV-1 |
| Q37730206 | Enhanced antibody responses to an HIV-1 membrane-proximal external region antigen in mice reconstituted with cultured lymphocytes |
| Q34016211 | Envelope deglycosylation enhances antigenicity of HIV-1 gp41 epitopes for both broad neutralizing antibodies and their unmutated ancestor antibodies |
| Q42287446 | Epitope Specificity of Cross‐Clade Neutralizing Sera from Chinese HIV‐1‐Positive Individuals |
| Q33888559 | Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects |
| Q37426168 | Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses |
| Q42959357 | Epitopes for broad and potent neutralizing antibody responses during chronic infection with human immunodeficiency virus type 1. |
| Q33518005 | Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies |
| Q45351263 | Expression and immunological characterization of cardamom mosaic virus coat protein displaying HIV gp41 epitopes |
| Q43488425 | Fusion intermediates of HIV-1 gp41 as targets for antibody production: design, synthesis, and HR1-HR2 complex purification and characterization of generated antibodies. |
| Q38721146 | Generation and characterization of a monoclonal antibody against duck Tembusu virus envelope protein |
| Q27022055 | HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design |
| Q36874604 | HIV-1 gp41 envelope IgA is frequently elicited after transmission but has an initial short response half-life. |
| Q21090490 | HIV-1 superinfection in women broadens and strengthens the neutralizing antibody response |
| Q35096836 | HIV-1-specific antibody responses during acute and chronic HIV-1 infection |
| Q33837481 | Identification of a conserved JEV serocomplex B-cell epitope by screening a phage-display peptide library with a mAb generated against West Nile virus capsid protein |
| Q38819865 | Identification of a conserved linear epitope using a monoclonal antibody against non-structural protein 3B of foot-and-mouth disease virus |
| Q34488183 | Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library |
| Q40051760 | Identification of a serotype-independent linear epitope of foot-and-mouth disease virus |
| Q34428738 | Identification of amino acid substitutions associated with neutralization phenotype in the human immunodeficiency virus type-1 subtype C gp120. |
| Q34324992 | Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodies |
| Q33951093 | Identification of two linear B-cell epitopes from West Nile virus NS1 by screening a phage-displayed random peptide library |
| Q38112585 | Immune response to HIV |
| Q39229789 | Immunization with hybrid proteins containing the membrane proximal external region of HIV-1. |
| Q34177732 | Immunoglobulin gene insertions and deletions in the affinity maturation of HIV-1 broadly reactive neutralizing antibodies |
| Q27312171 | Induction of Antibodies in Rhesus Macaques That Recognize a Fusion-Intermediate Conformation of HIV-1 gp41 |
| Q36978671 | Infectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccinees |
| Q41846910 | Interactions of peptide triazole thiols with Env gp120 induce irreversible breakdown and inactivation of HIV-1 virions |
| Q35043547 | Is developing an HIV-1 vaccine possible? |
| Q34784621 | MABGEL 1: first phase 1 trial of the anti-HIV-1 monoclonal antibodies 2F5, 4E10 and 2G12 as a vaginal microbicide |
| Q57452585 | Mapping of neutralizing antibody epitopes on the envelope of viruses obtained from plasma samples exhibiting broad cross-clade neutralization potential against HIV-1 |
| Q53695792 | Molecular basis of unusually high neutralization resistance in tier 3 HIV-1 strain 253-11. |
| Q35881238 | N-terminal residues of an HIV-1 gp41 membrane-proximal external region antigen influence broadly neutralizing 2F5-like antibodies |
| Q28483205 | Neutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from India |
| Q37519312 | Neutralizing antibodies generated during natural HIV-1 infection: good news for an HIV-1 vaccine? |
| Q38058120 | Non-neutralizing antibodies in prevention of HIV infection |
| Q43096886 | Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. |
| Q47269868 | Optimization of the EC26-2A4 epitope in the gp41 membrane proximal external region (MPER) targeted by neutralizing antibodies from an elite controller |
| Q24635002 | Polyclonal B cell responses to conserved neutralization epitopes in a subset of HIV-1-infected individuals |
| Q56892297 | Prime boost vaccination approaches with different conjugates of a new HIV-1 gp41 epitope encompassing the membrane proximal external region induce neutralizing antibodies in mice |
| Q27693849 | Progress in HIV-1 vaccine development. |
| Q33778466 | Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution |
| Q36559735 | Proteolytic Processing of the Human Immunodeficiency Virus Envelope Glycoprotein Precursor Decreases Conformational Flexibility |
| Q35973587 | Rapid Development of gp120-Focused Neutralizing B Cell Responses during Acute Simian Immunodeficiency Virus Infection of African Green Monkeys |
| Q29619511 | Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1 |
| Q28484544 | Recognition of membrane-bound fusion-peptide/MPER complexes by the HIV-1 neutralizing 2F5 antibody: implications for anti-2F5 immunogenicity |
| Q27680872 | Structural Basis for HIV-1 Neutralization by 2F5-Like Antibodies m66 and m66.6 |
| Q35998559 | Targeting antibody responses to the membrane proximal external region of the envelope glycoprotein of human immunodeficiency virus |
| Q37789346 | The humoral response to HIV-1: new insights, renewed focus. |
| Q34614862 | The immune response during acute HIV-1 infection: clues for vaccine development |
| Q37667754 | The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. |
Search more.